Sebela Women’s Health

Sebela Women's Health is the specialized division of Sebela Pharmaceuticals, a US-based specialty pharmaceutical company focused on women's health, gastroenterology, and dermatology. The company significantly expanded its presence in the women's health market through the 2022 acquisition of TherapeuticsMD's commercial assets, including Imvexxy and Bijuva. Its current commercial portfolio addresses critical needs in menopause management, specifically moderate-to-severe vasomotor symptoms and dyspareunia. In addition to its marketed products, Sebela is advancing VeraCept, a novel, low-dose copper intrauterine device (IUD) currently in Phase 3 clinical development. The company is headquartered in Roswell, Georgia, and is backed by the private equity firm Water Street Healthcare Partners.